Thanks. I'll take it. FWIW there is at least one approved drug for which I read the Statistical Review that had only 2 ph iii trials, both just barely failing. The statistician recommended rejection on the same basis that you just espoused, but was overruled. What I don't remember is the particular drug, nor the amount of ph ii data. If I find it again I'll post it.
BTW - Neat trick, that "you can have the last word".